source
- PepGen stock surges as DM1 oligonucleotide PGN-EDODM1 shows record splicing correction in Phase 2PepGen reported that its experimental oligonucleotide PGN-EDODM1 achieved a mean splicing correction of 46.5% at week 13 in a Phase 2 trial for myotonic dystrophy type 1 (DM1). This performance exc…
- Flagship-backed Valo Health merges with Montai Therapeutics to boost AI-driven drug pipelineValo Health and Montai Therapeutics announced they will combine under the Valo brand, creating a larger AI-focused biotech aimed at accelerating early-stage drug discovery. Valo, launched in 2020…